Belite Bio, Inc (BLTE): Price and Financial Metrics

Belite Bio, Inc (BLTE): $69.90

3.29 (+4.94%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add BLTE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#91 of 328

in industry

BLTE Price/Volume Stats

Current price $69.90 52-week high $70.36
Prev. close $66.61 52-week low $31.00
Day low $65.75 Volume 134,100
Day high $70.00 Avg. volume 51,637
50-day MA $53.10 Dividend yield N/A
200-day MA $47.14 Market Cap 2.14B

BLTE Stock Price Chart Interactive Chart >


Belite Bio, Inc (BLTE) Company Bio


Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.


BLTE Latest News Stream


Event/Time News Detail
Loading, please wait...

BLTE Latest Social Stream


Loading social stream, please wait...

View Full BLTE Social Stream

BLTE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!